{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:23:23Z","timestamp":1794587003602,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Kabuki Syndrome (KS) is a rare disorder characterized by distinctive facial features, short stature, skeletal abnormalities, and neurodevelopmental deficits. Previously, we showed that loss of function of RAP1A, a RAF1 regulator, can activate the RAS\/MAPK pathway and cause KS, an observation recapitulated in other genetic models of the disorder. These data suggested that suppression of this signaling cascade might be of therapeutic benefit for some features of KS. To pursue this possibility, we performed a focused small molecule screen of a series of RAS\/MAPK pathway inhibitors, where we tested their ability to rescue disease-relevant phenotypes in a zebrafish model of the most common KS locus, <jats:italic>kmt2d<\/jats:italic>. Consistent with a pathway-driven screening paradigm, two of 27 compounds showed reproducible rescue of early developmental pathologies. Further analyses showed that one compound, desmethyl-Dabrafenib (dmDf), induced no overt pathologies in zebrafish embryos but could rescue MEK hyperactivation <jats:italic>in vivo<\/jats:italic> and, concomitantly, structural KS-relevant phenotypes in all KS zebrafish models (<jats:italic>kmt2d<\/jats:italic>, <jats:italic>kmd6a<\/jats:italic> and <jats:italic>rap1<\/jats:italic>). Mass spectrometry quantitation suggested that a 100\u2009nM dose resulted in sub-nanomolar exposure of this inhibitor and was sufficient to rescue both mandibular and neurodevelopmental defects. Crucially, germline <jats:italic>kmt2d<\/jats:italic> mutants recapitulated the gastrulation movement defects, micrognathia and neurogenesis phenotypes of transient models; treatment with dmDf ameliorated all of them significantly. Taken together, our data reinforce a causal link between MEK hyperactivation and KS and suggest that chemical suppression of BRAF might be of potential clinical utility for some features of this disorder.<\/jats:p>","DOI":"10.1038\/s41598-018-28709-y","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T10:19:48Z","timestamp":1531304388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Small molecule inhibition of RAS\/MAPK signaling ameliorates developmental pathologies of Kabuki Syndrome"],"prefix":"10.1038","volume":"8","author":[{"given":"I-Chun","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer U.","family":"McKinstry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1918-2647","authenticated-orcid":false,"given":"Perciliz L.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Golzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Thomas","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-8397","authenticated-orcid":false,"given":"Erica E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Amrine-Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Katsanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,17]]},"reference":[{"key":"28709_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/ejhg.2011.220","volume":"20","author":"S Banka","year":"2012","unstructured":"Banka, S. et al. How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in 116 patients, review and analyses of mutation and phenotypic spectrum. Eur J Hum Genet 20, 381\u20138 (2012).","journal-title":"Eur J Hum Genet"},{"key":"28709_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/cge.12051","volume":"83","author":"N Bogershausen","year":"2013","unstructured":"Bogershausen, N. & Wollnik, B. Unmasking Kabuki syndrome. Clin Genet 83, 201\u201311 (2013).","journal-title":"Clin Genet"},{"key":"28709_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S0022-3476(81)80256-9","volume":"99","author":"Y Kuroki","year":"1981","unstructured":"Kuroki, Y., Suzuki, Y., Chyo, H., Hata, A. & Matsui, I. A new malformation syndrome of long palpebral fissures, large ears, depressed nasal tip, and skeletal anomalies associated with postnatal dwarfism and mental retardation. J Pediatr 99, 570\u20133 (1981).","journal-title":"J Pediatr"},{"key":"28709_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0022-3476(81)80255-7","volume":"99","author":"N Niikawa","year":"1981","unstructured":"Niikawa, N., Matsuura, N., Fukushima, Y., Ohsawa, T. & Kajii, T. Kabuki make-up syndrome: a syndrome of mental retardation, unusual faces, large and protruding ears, and postnatal growth deficiency. J Pediatr 99, 565\u20139 (1981).","journal-title":"J Pediatr"},{"key":"28709_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1399-0004.2004.00348.x","volume":"67","author":"MP Adam","year":"2005","unstructured":"Adam, M. P. & Hudgins, L. Kabuki syndrome: a review. Clin Genet 67, 209\u201319 (2005).","journal-title":"Clin Genet"},{"key":"28709_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/archdischild-2013-305858","volume":"100","author":"ML Dentici","year":"2015","unstructured":"Dentici, M. L. et al. Kabuki syndrome: clinical and molecular diagnosis in the first year of life.\u00a0Archives of Disease in Childhood 100, 158\u2013164\u00a0(2015).","journal-title":"Archives of Disease in Childhood"},{"key":"28709_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/ajmg.a.30331","volume":"132A","author":"CTRM Schrander\u2010Stumpel","year":"2005","unstructured":"Schrander\u2010Stumpel, C. T. R. M. et al. Kabuki syndrome: Clinical data in 20 patients, literature review, and further guidelines for preventive management. American Journal of Medical Genetics Part A 132A, 234\u2013243 (2005).","journal-title":"American Journal of Medical Genetics Part A"},{"key":"28709_CR8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ng.646","volume":"42","author":"SB Ng","year":"2010","unstructured":"Ng, S. B. et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet 42, 790\u20133 (2010).","journal-title":"Nat Genet"},{"key":"28709_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00439-011-1004-y","volume":"130","author":"Y Li","year":"2011","unstructured":"Li, Y. et al. A mutation screen in patients with Kabuki syndrome. Hum Genet 130, 715\u201324 (2011).","journal-title":"Hum Genet"},{"key":"28709_CR10","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.3892\/mmr.2016.5683","volume":"14","author":"J Lu","year":"2016","unstructured":"Lu, J., Mo, G., Ling, Y. & Ji, L. A novel KMT2D mutation resulting in Kabuki syndrome: A case report. Mol Med Rep 14, 3641\u20135 (2016).","journal-title":"Mol Med Rep"},{"key":"28709_CR11","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1002\/ajmg.a.36072","volume":"161a","author":"N Miyake","year":"2013","unstructured":"Miyake, N. et al. MLL2 and KDM6A mutations in patients with Kabuki syndrome. Am J Med Genet A 161a, 2234\u201343 (2013).","journal-title":"Am J Med Genet A"},{"key":"28709_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/humu.22229","volume":"34","author":"N Miyake","year":"2013","unstructured":"Miyake, N. et al. KDM6A point mutations cause Kabuki syndrome. Hum Mutat 34, 108\u201310 (2013).","journal-title":"Hum Mutat"},{"key":"28709_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ajhg.2011.11.021","volume":"90","author":"D Lederer","year":"2012","unstructured":"Lederer, D. et al. Deletion of KDM6A, a Histone Demethylase Interacting with MLL2, in Three Patients with Kabuki Syndrome. Am J Hum Genet 90, 119\u201324 (2012).","journal-title":"Am J Hum Genet"},{"key":"28709_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/35073073","volume":"2","author":"JL Bos","year":"2001","unstructured":"Bos, J. L., de Rooij, J. & Reedquist, K. A. Rap1 signalling: adhering to new models. Nat Rev Mol Cell Biol 2, 369\u201377 (2001).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"28709_CR15","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1172\/JCI80102","volume":"125","author":"N Bogershausen","year":"2015","unstructured":"Bogershausen, N. et al. RAP1-mediated MEK\/ERK pathway defects in Kabuki syndrome. J Clin Invest 125, 3585\u201399 (2015).","journal-title":"J Clin Invest"},{"key":"28709_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/02699050500284218","volume":"24","author":"S Yoon","year":"2006","unstructured":"Yoon, S. & Seger, R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24, 21\u201344 (2006).","journal-title":"Growth Factors"},{"key":"28709_CR17","doi-asserted-by":"publisher","first-page":"11702","DOI":"10.1074\/jbc.272.18.11702","volume":"272","author":"CD Hu","year":"1997","unstructured":"Hu, C. D. et al. Coassociation of Rap1A and Ha-Ras with Raf-1 N-terminal region interferes with ras-dependent activation of Raf-1. J Biol Chem 272, 11702\u20135 (1997).","journal-title":"J Biol Chem"},{"key":"28709_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0092-8674(00)80184-1","volume":"89","author":"MR Vossler","year":"1997","unstructured":"Vossler, M. R. et al. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 89, 73\u201382 (1997).","journal-title":"Cell"},{"key":"28709_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/33451","volume":"392","author":"RD York","year":"1998","unstructured":"York, R. D. et al. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 392, 622\u20136 (1998).","journal-title":"Nature"},{"key":"28709_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","volume":"19","author":"WE Tidyman","year":"2009","unstructured":"Tidyman, W. E. & Rauen, K. A. The RASopathies: developmental syndromes of Ras\/MAPK pathway dysregulation. Curr Opin Genet Dev 19, 230\u20136 (2009).","journal-title":"Curr Opin Genet Dev"},{"key":"28709_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","volume":"14","author":"KA Rauen","year":"2013","unstructured":"Rauen, K. A. The RAS opathies. Annu Rev Genomics Hum Genet 14, 355\u201369 (2013).","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"28709_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14728222.2011.645805","volume":"16","author":"L Santarpia","year":"2012","unstructured":"Santarpia, L., Lippman, S. M. & El-Naggar, A. K. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16, 103\u201319 (2012).","journal-title":"Expert Opin Ther Targets"},{"key":"28709_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u201354 (2002).","journal-title":"Nature"},{"key":"28709_CR24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1517\/17425255.2013.794220","volume":"9","author":"GT Gibney","year":"2013","unstructured":"Gibney, G. T. & Zager, J. S. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol 9, 893\u20139 (2013).","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"28709_CR25","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1172\/JCI44929","volume":"121","author":"X Wu","year":"2011","unstructured":"Wu, X. et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation.\u00a0The Journal of Clinical Investigation 121, 1009\u20131025\u00a0(2011).","journal-title":"The Journal of Clinical Investigation"},{"key":"28709_CR26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.cell.2012.06.034","volume":"150","author":"Y Wang","year":"2012","unstructured":"Wang, Y. et al. RAS\/ERK inhibition rescues fate-specification defects of Nf1-deficient neural progenitors and brain abnormalities. Cell 150, 816\u201330 (2012).","journal-title":"Cell"},{"key":"28709_CR27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ng.97","volume":"40","author":"CC Leitch","year":"2008","unstructured":"Leitch, C. C. et al. Hypomorphic mutations in syndromic encephalocele genes are associated with Bardet-Biedl syndrome. Nat Genet 40, 443\u20138 (2008).","journal-title":"Nat Genet"},{"key":"28709_CR28","doi-asserted-by":"publisher","first-page":"e10367","DOI":"10.1371\/journal.pone.0010367","volume":"5","author":"S Sarmah","year":"2010","unstructured":"Sarmah, S. et al. Sec. 24D-dependent transport of extracellular matrix proteins is required for zebrafish skeletal morphogenesis. Plos One 5, e10367 (2010).","journal-title":"Plos One"},{"key":"28709_CR29","doi-asserted-by":"publisher","first-page":"11728","DOI":"10.1074\/jbc.M808991200","volume":"284","author":"JJ Zoeller","year":"2009","unstructured":"Zoeller, J. J. et al. A central role for decorin during vertebrate convergent extension. J Biol Chem 284, 11728\u201337 (2009).","journal-title":"J Biol Chem"},{"key":"28709_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.vascn.2008.05.130","volume":"58","author":"S Berghmans","year":"2008","unstructured":"Berghmans, S. et al. Zebrafish based assays for the assessment of cardiac, visual and gut function\u2013potential safety screens for early drug discovery. J Pharmacol Toxicol Methods 58, 59\u201368 (2008).","journal-title":"J Pharmacol Toxicol Methods"},{"key":"28709_CR31","unstructured":"Cao, J. et al. Heterocyclic inhibitors of erk2 and uses thereof. WO 2002064586 A2."},{"key":"28709_CR32","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1124\/dmd.113.053785","volume":"41","author":"DA Bershas","year":"2013","unstructured":"Bershas, D. A. et al. Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation. Drug Metab Dispos 41, 2215\u201324 (2013).","journal-title":"Drug Metab Dispos"},{"key":"28709_CR33","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s40265-013-0095-2","volume":"73","author":"AD Ballantyne","year":"2013","unstructured":"Ballantyne, A. D. & Garnock-Jones, K. P. Dabrafenib: first global approval. Drugs 73, 1367\u201376 (2013).","journal-title":"Drugs"},{"key":"28709_CR34","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","volume":"379","author":"GS Falchook","year":"2012","unstructured":"Falchook, G. S. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893\u2013901 (2012).","journal-title":"Lancet"},{"key":"28709_CR35","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1517\/14740338.2014.939954","volume":"13","author":"P Rutkowski","year":"2014","unstructured":"Rutkowski, P. & Blank, C. Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation. Expert Opin Drug Saf 13, 1249\u201358 (2014).","journal-title":"Expert Opin Drug Saf"},{"key":"28709_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1756-8722-6-30","volume":"6","author":"T Huang","year":"2013","unstructured":"Huang, T., Karsy, M., Zhuge, J., Zhong, M. & Liu, D. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol 6, 30 (2013).","journal-title":"J Hematol Oncol"},{"key":"28709_CR37","doi-asserted-by":"crossref","unstructured":"Leonard, H., Cobb, S. & Downs, J. Clinical and biological progress over 50 years in Rett syndrome. Nat Rev Neurol (2016).","DOI":"10.1038\/nrneurol.2016.186"},{"key":"28709_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11065-010-9148-4","volume":"20","author":"J Stiles","year":"2010","unstructured":"Stiles, J. & Jernigan, T. L. The basics of brain development. Neuropsychol Rev 20, 327\u201348 (2010).","journal-title":"Neuropsychol Rev"},{"key":"28709_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00019605-200204000-00004","volume":"11","author":"MW Wessels","year":"2002","unstructured":"Wessels, M. W., Brooks, A. S., Hoogeboom, J., Niermeijer, M. F. & Willems, P. J. Kabuki syndrome: a review study of three hundred patients. Clin Dysmorphol 11, 95\u2013102 (2002).","journal-title":"Clin Dysmorphol"},{"key":"28709_CR40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1101\/gr.176925.114","volume":"25","author":"G Borck","year":"2015","unstructured":"Borck, G. et al. BRF1 mutations alter RNA polymerase III-dependent transcription and cause neurodevelopmental anomalies. Genome Res 25, 609 (2015).","journal-title":"Genome Res"},{"key":"28709_CR41","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1534\/genetics.114.168211","volume":"198","author":"SS Brooks","year":"2014","unstructured":"Brooks, S. S. et al. A novel ribosomopathy caused by dysfunction of RPL10 disrupts neurodevelopment and causes X-linked microcephaly in humans. Genetics 198, 723\u201333 (2014).","journal-title":"Genetics"},{"key":"28709_CR42","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.ajhg.2015.11.005","volume":"97","author":"JA O\u2019Rawe","year":"2015","unstructured":"O\u2019Rawe, J. A. et al. TAF1 Variants Are Associated with Dysmorphic Features, Intellectual Disability, and Neurological Manifestations. Am J Hum Genet 97, 922\u201332 (2015).","journal-title":"Am J Hum Genet"},{"key":"28709_CR43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ajhg.2014.12.013","volume":"96","author":"SB Wortmann","year":"2015","unstructured":"Wortmann, S. B. et al. CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder. Am J Hum Genet 96, 245\u201357 (2015).","journal-title":"Am J Hum Genet"},{"key":"28709_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/ajmg.c.10020","volume":"117C","author":"N Matsumoto","year":"2003","unstructured":"Matsumoto, N. & Niikawa, N. Kabuki make-up syndrome: a review. Am J Med Genet C Semin Med Genet 117C, 57\u201365 (2003).","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"28709_CR45","doi-asserted-by":"crossref","unstructured":"Bjornsson, H. T. et al. Histone deacetylase inhibition rescues structural and functional brain deficits in a mouse model of Kabuki syndrome. Sci Transl Med 6, 256ra135 (2014).","DOI":"10.1126\/scitranslmed.3009278"},{"key":"28709_CR46","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1093\/hmg\/ddv180","volume":"24","author":"PM Van Laarhoven","year":"2015","unstructured":"Van Laarhoven, P. M. et al. Kabuki syndrome genes KMT2D and KDM6A: functional analyses demonstrate critical roles in craniofacial, heart and brain development. Hum Mol Genet 24, 4443\u201353 (2015).","journal-title":"Hum Mol Genet"},{"key":"28709_CR47","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1185\/03007995.2012.673480","volume":"28","author":"P Sun","year":"2012","unstructured":"Sun, P. & Garrison, L. P. Retrospective outcomes studies for orphan diseases: challenges and opportunities. Curr Med Res Opin 28, 665\u20137 (2012).","journal-title":"Curr Med Res Opin"},{"key":"28709_CR48","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1128\/AAC.03588-14","volume":"59","author":"A Ordas","year":"2015","unstructured":"Ordas, A. et al. Testing tuberculosis drug efficacy in a zebrafish high-throughput translational medicine screen. Antimicrob Agents Chemother 59, 753\u201362 (2015).","journal-title":"Antimicrob Agents Chemother"},{"key":"28709_CR49","doi-asserted-by":"crossref","unstructured":"Wang, G. et al. First quantitative high-throughput screen in zebrafish identifies novel pathways for increasing pancreatic beta-cell mass. Elife 4 (2015).","DOI":"10.7554\/eLife.08261"},{"key":"28709_CR50","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/jmedgenet-2012-100892","volume":"49","author":"N Chassaing","year":"2012","unstructured":"Chassaing, N. et al. OTX2 mutations contribute to the otocephaly-dysgnathia complex. J Med Genet 49, 373\u20139 (2012).","journal-title":"J Med Genet"},{"key":"28709_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/srep06420","volume":"4","author":"X Zhu","year":"2014","unstructured":"Zhu, X. et al. An efficient genotyping method for genome-modified animals and human cells generated with CRISPR\/Cas9 system. Sci Rep 4, 6420 (2014).","journal-title":"Sci Rep"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28709-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28709-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28709-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:45:30Z","timestamp":1671608730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28709-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,17]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["28709"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-28709-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,17]]},"assertion":[{"value":"18 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.K., I.C.T. and S.U.M. are paid consultants of Rescindo Therapeutics Inc. N.K. also holds founder stock of the same commercial entity. K.M. and S.U.M. received fellowship awards from G.S.K. and S.U.M. is a current G.S.K. postdoctoral Fellow. H.A.-M., A.T.M., D.J.P. and C.T.W. were paid employees of G.S.K. at the time of this research. P.L.T., C.G. and E.E.D. declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10779"}}